pembrolizumab,lenvatinib
merck,eisai
['hcc', 'agent', 'key,note,24', 'lenva', 'keynote-240', 'pembro']
 precisely as expected from pembrolizumab's single-agent activity in #hcc (keynote-240).
vs placebo, pembro raised pfs 13% &amp; 10% at 12 &amp; 24 months expected benefit plus lenvatinib is
12 mo: 29% -&gt; 35%
24 mo: 9% -&gt; 15% see this paper on 13 other combos: 
Assistant Professor, Pharmacology and Computational Medicine at @UNC
Measuring and modeling combination cancer therapy